CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG) Files An 8-K Regulation FD DisclosureItem 7.01Regulation FD Disclosure.
On June 22, 2018, Cellular Biomedicine Group, Inc. (the “Company”) issued a press release announcing the grand opening of its new research and development center in Gaithersburg, Maryland. A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
99.1 Press Release, dated June 22, 2018
Cellular Biomedicine Group, Inc. ExhibitEX-99.1 2 cbmg_ex991.htm PRESS RELEASE Blueprint Exhibit 99.1 Cellular Biomedicine Group Announces Grand Opening of Global Research and Development Center in Gaithersburg,…To view the full exhibit click
About CELLULAR BIOMEDICINE GROUP, INC. (NASDAQ:CBMG)
Cellular Biomedicine Group, Inc. (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. It is focused on developing and marketing cell-based therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases, including osteoarthritis and tissue damage, various inflammatory diseases and metabolic diseases.